Phase 2 biotech developing obesity therapies by targeting metabolic aging.
Industry: Health Care
Latest Trade: ()
First Day Return:
Return from IPO:
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/03/2024 |
Offer Price | |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 7.5 |
Deal Size ($mm) | $135 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | |
Offer Price | |
Price Range $17.00 - $19.00 | |
Offer Shares (mm) | 7.5 |
Deal Size ($mm) | $135 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
Morgan Stanley |
more |
Company Data | |
---|---|
Headquarters | Richmond, CA, United States |
Founded | 2015 |
Employees at IPO | 60 |
Website bioagelabs.com |